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Background: Left ventricular dysfunction post STEMI is associated with increased mortality and morbidity. Current therapies limit damage but 
do not repair already damaged myocardium. Several clinical trials have illustrated that administration of autologous intracoronary bone marrow 
stem cells (BMSC) post STEMI may lead to improved left ventricular ejection fraction (LVEF). A mouse model of myocardial infarction demonstrated 
improved mortality and LVEF in animals where BMSC were mobilized by Granulocyte colony stimulating factor (G-CSF).
In patients with STEMI, G-CSF therapy may promote mobilization of BMSC that may help in myocardial repair and improve LVEF.
Methods: Patients with a successfully reperfused STEMI with primary PCI, who were within 1 week of their STEMI, were enrolled. Groups were 
randomized using a double-blind placebo controlled protocol, to optimal medical therapy and G-CSF therapy vs. optimal medical therapy and 
placebo. G-CSF therapy consisted of 10 μg/kg sc injection for 4 days commencing day 4 post STEMI. Each patient had a baseline left ventricular 
radionuclide angiogram (LV RNA), FDG PET, and N-13-Ammonia PET scan. The LV RNA will be repeated in 6 weeks and 6 months to assess for 
recovery. The FDG PET and N-13-Ammonia PET will be repeated at 6 weeks. As well, the patients WBC’s and CD34+ cells will be monitored during 
G-CSF therapy to assess for stem cell mobilization. All patients will be followed for clinical events. Primary endpoint was change in 6 month LVEF vs. 
baseline LVEF.
Results: 86 patients were enrolled and randomized. 6 month follow-up will be completed as of June 30, 2010. There were 70 males, average 
age 54.9±9, and baseline LVEF 35.6% ±9.2 %. There were 35% of patients with hypertension, 44% smokers, 40% with dyslipidemia, and 22% with 
diabetes mellitus. At 6 months there have been 2 deaths, 2 re-infarctions, 2 cardiac transplants, 7 re-admissions for CHF, 1 CVA, and 12 repeat 
revascularizations.
Conclusions: Patient recruitment is complete and complete 6 month LVEF and clinical follow-up will be completed shortly. This study will add vital 
information regarding stem cell therapy in patients with low LVEF.
